ProfileGDS5678 / 1454645_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 89% 88% 88% 90% 88% 89% 90% 89% 89% 89% 89% 89% 89% 89% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.9250189
GSM967853U87-EV human glioblastoma xenograft - Control 26.8814888
GSM967854U87-EV human glioblastoma xenograft - Control 36.8717288
GSM967855U87-EV human glioblastoma xenograft - Control 47.4596590
GSM967856U87-EV human glioblastoma xenograft - Control 56.9982488
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.7871489
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.0074490
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.0366789
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.0253789
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.0519489
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.9271589
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.0597689
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.0089389
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.0222689